Benjamin T. Dake, SEE REMARKS at Aerovate Therapeutics, Inc. (AVTE), sold 28,674 shares at $15.74 ($441K) on 2023-11-24, disclosed to the SEC on 2023-11-27.
Scheduled sale ($441k) by SEE REMARKS under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.17 | 9,382 | $142K | 32.3% |
| 2 | $15.17 | 9,382 | $142K | 32.3% |
| 3 | $15.74 | 4,920 | $77K | 17.6% |
| 4 | $15.74 | 4,920 | $77K | 17.6% |
| 5 | $16.07 | 70 | $1K | 0.3% |
| Total | $15.37 avg | 28,674 |
| $441K |
| 100% |
| Filing → |
| AVTE | SELL | 2024-03-28 | $619K | — | Filing → |
| AVTE | SELL | 2024-03-27 | $192K | — | Filing → |
| AVTE | SELL | 2024-03-20 | $1.8M | — | Filing → |